Summary Slide.png (79.71 kB)

Cost-Effectiveness Analysis of Linagliptin in Japan Based on Results from the Asian Subpopulation in the CARMELINA® Trial

figure

posted on 2020-06-15, 09:46 authored by Hirotaka Watada, Hiroyuki Sakamaki, Daisuke Yabe, Fumiko Yamamoto, Tatsunori Murata, Keigo Hanada, Tetsuaki Hirase, Tomoo Okamura

The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

History

Usage metrics

Keywords

Cardiorenal events CARMELINA trial Cost-effectiveness analysis Diabetes DPP-4 inhibitor ICER Japan Linagliptin MACE QALY

Licence

CC BY-NC 4.0

Cost-Effectiveness Analysis of Linagliptin in Japan Based on Results from the Asian Subpopulation in the CARMELINA® Trial

History

Usage metrics

Categories

Keywords

Licence

Exports